Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PB-201 Phase 1 Crossover Study in T2DM
NCT03973515Phase 1Completed
- Sponsor
- PegBio
- Start
- Aug 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nerigliatin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by PegBio. Primary endpoints: Time to peak plasma concentration at 9 days, Peak Plasma Concentration at 9 days and 1 more. Started Aug 2019; status: completed.
02
Drugs
nerigliatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03973515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03973515.